SiBone (NASDAQ:SIBN) Stock: Insider Anshul Maheshwari Sells 3,247 Shares

Key Points

• Insider Anshul Maheshwari sold 3,247 Si-Bone shares at an average price of $25, totaling $81,175. He retained 211,250 shares after the sale.
• Si-Bone reported quarterly adjusted losses of $0.08 per share, better than analysts’ $0.13 loss estimate, while revenue of $55.7 million also exceeded expectations.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $25. The stock recently traded at $24.24.

SiBone (NASDAQ:SIBN - Get Free Report) insider Anshul Maheshwari sold 3,247 shares of the company's stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $25.00, for a total transaction of $81,175.00. Following the completion of the transaction, the insider owned 211,250 shares in the company, valued at $5,281,250. This trade represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Anshul Maheshwari also recently made the following trade(s):

• On Thursday, October 29th, Anshul Maheshwari sold 3,738 shares of SiBone stock. The stock was sold at an average price of $22.50, for a total transaction of $84,105.00.
• On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The shares were sold at an average price of $19.50, for a total value of $33,754.50.
• On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The shares were sold at an average price of $18.18, for a total transaction of $60,321.24.
• On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The stock was sold at an average price of $20.11, for a total transaction of $233,999.96.
• On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $224,784.56.
• On Wednesday, August 19th, Anshul Maheshwari sold 5,747 shares of SiBone stock. The shares were sold at an average price of $19.55, for a total transaction of $112,353.85.
• On Monday, August 17th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The stock was sold at an average price of $18.65, for a total value of $87,002.25.

SiBone Trading Down 0.1%

SIBN stock traded down $0.03 during trading on Friday, hitting $24.24. The company had a trading volume of 683,472 shares, compared to its average volume of 638,581. SiBone has a one year low of $11.48 and a one year high of $25.92. The company has a current ratio of 7.58, a quick ratio of 7.55 and a debt-to-equity ratio of 0.19. The business has a 50-day moving average of $19.71 and a 200-day moving average of $16.56. The stock has a market cap of $1.09 billion, a PE ratio of -78.19 and a beta of 0.64.

SiBone (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. The firm had revenue of $55.70 million for the quarter, compared to analysts' expectations of $55.31 million. SiBone had a negative return on equity of 7.57% and a negative net margin of 6.20%. Research analysts predict that SiBone will post -0.34 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Versant Capital Management Inc boosted its stake in shares of SiBone by 102.9% during the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company's stock valued at $29,000 after purchasing an additional 887 shares during the period. State of Wyoming lifted its holdings in SiBone by 70.8% in the first quarter. State of Wyoming now owns 10,832 shares of the company's stock worth $137,000 after buying an additional 4,490 shares during the period. Inceptionr LLC purchased a new stake in SiBone in the first quarter worth $156,000. ADAR1 Capital Management LLC bought a new position in shares of SiBone in the 1st quarter worth about $159,000. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of SiBone during the first quarter valued at approximately $204,000. Hedge funds and other institutional investors own 98.11% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Citigroup reiterated a "market outperform" rating on shares of SiBone in a research note on Tuesday. Needham & Company LLC lowered their target price on shares of SiBone from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Tuesday. UBS Group lifted their target price on SiBone from $25.00 to $26.00 and gave the company a "buy" rating in a report on Tuesday. Weiss Ratings raised shares of SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, August 20th. Finally, TD Cowen increased their price objective on SiBone from $20.00 to $23.00 and gave the stock a "buy" rating in a research report on Tuesday. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $25.00.

About SiBone

SI-BONE, Inc NASDAQ: SIBN is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.